EICHOR
● Active Not Recruiting
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
Condition: Neovascular Age-related Macular Degeneration (nAMD) · Sponsor: Hoffmann-La Roche
About this study
This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (67)
| Orange County Retina Medical Group | Santa Ana, California, United States | — |
| Florida Retina Institute | Orlando, Florida, United States | — |
| Ctr for Retina & Macular Dis | Winter Haven, Florida, United States | — |
| Retinal Vitreal Consultants | Chicago, Illinois, United States | — |
| University Retina and Macula Associates, PC | Lemont, Illinois, United States | — |
| New England Retina Consultants | Springfield, Massachusetts, United States | — |
| Sierra Eye Associates | Sparks, Nevada, United States | — |
| Retina Associates of New Jersey | Teaneck, New Jersey, United States | — |
| Vision Research Center at Eye Associates of New Mexico | Albuquerque, New Mexico, United States | — |
| Charles Retina Institute | Germantown, Tennessee, United States | — |
| Retina Consultants of Texas | Schertz, Texas, United States | — |
| Strathfield Retina Clinic | Strathfield, New South Wales, Australia | — |
+ 55 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06795048